
Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.

Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.

Arun Azad, PhD, discusses the design of the phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer.

Arun Azad, PhD, discusses the utility of adding enzalutamide to androgen deprivation therapy in subgroups of men with metastatic hormone-sensitive prostate cancer.

Arun Azad, PhD, discusses the results of the post-hoc analyses of the phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer.

Arun Azad, PhD, discusses unmet needs for men with metastatic hormone-sensitive prostate cancer.

October 20th 2020

October 22nd 2020